Health care stocks were mixed Friday afternoon, with the NYSE Health Care Index easing 0.01% and the Health Care Select Sector SPDR Fund (XLV) adding 0.1%.

The iShares Biotechnology ETF (IBB) was shedding 0.5%.

In corporate news, Amgen's (AMGN) Uplizna has received a positive opinion from the European Medicines Agency's human medicines committee recommending its approval for adults with active immunoglobulin G4-related disease, a rare autoimmune disorder with no authorized treatments in the EU. Amgen shares rose past 3%.

InterCure (INCR) shares were down 1.4% after it said Friday it has agreed to buy medical cannabis brand and technology company Botanico, also known as ISHI, in a two-phase deal valued at about 10% of InterCure's outstanding shares on a fully-diluted basis.

ARS Pharmaceuticals (SPRY) shares added nearly 1% after the company said its nasal spray Neffy has received regulatory approval in Japan for the emergency treatment of allergic reactions, including anaphylaxis.